Marcy l'Etoile, France - September 18, 2006. bioMérieux’s board of Directors, which met on Friday, September 15th in Marcy l’Etoile, has appointed Jean-Luc Bélingard, President of the Ipsen Group, as board member.
Jean-Luc Bélingard’s acknowledged experience within the pharmaceutical and diagnostic industries, together with his vision, will enhance and strengthen the expertise of bioMérieux’s Board of Directors. Mr Bélingard will attend the Board of Directors to be held on December 15th, 2006.
With a degree from the French Grande Ecole “ Hautes Etudes Commerciales – HEC ” and an MBA from Cornell University (United States), Jean-Luc Bélingard, has been President and Chief Executive Officer of the Ipsen Group since January 2002. Before joining Ipsen, he held several positions within the international pharmaceutical industry, notably as Managing Director of the diagnostics division of Roche and as member of the Management Committee of Hoffman Laroche in Bâle.
Jean-Luc Bélingard also serves as a board member of Laboratory Corporation of America (United States), Applera Corporation (United States) and NicOx (France). He is also advisor to the French government on international trade, and since 2006, a board member of Inserm.
Jean-Luc Bélingard is also chief representative and spokesperson of G5, an association of five major French pharmaceutical companies: Ipsen, LFB, Pierre Fabre, Sanofi Aventis and Servier.